QIDP Roundup: Familiar Names Dominate 2019 Designations

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.

Antibiotic-resistant-bacteria

The US Food and Drug Administration’s Qualified Infectious Disease Product (QIDP) designation program is growing slowly, but it is growing, as 2019 has seen a rash of new designations in new indications for QIDP status for Iterum Therapeutics PLC’s penem antibiotic sulopenem and Polyphor Ltd.’s Pseudomonas-targeting murepavadin, as well as a QIDP for a third candidate from Spero Therapeutics Inc..

The QIDP designation count for Iterum’s sulopenem reached seven, thanks to new designations for community-acquired bacterial pneumonia (CABP), acute bacterial...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

PS-Pathways&Standards (Free-1): Industrial Chemicals Within Us - The Ubiquity of Industrial Products in the Human Body

 
• By Nabil

Exploring How Everyday Industrial Compounds Enter Our Systems, Their Health Implications, and the Ongoing Quest for Safer Alternatives .

Brazil Issues Guidance On Regulatory Reliance & Equivalent Authorities

 
• By Francesca Bruce

Brazilian regulator Anvisa is relying on the decisions of its foreign counterparts as a means of ensuring more quality medicines are made available in the country.

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

 
• By Sue Sutter

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By Ian Schofield

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.

More from Pathways & Standards

Anvisa To Access US FDA-Reviewed Data For More Robust Evaluations In Brazil

 
• By Francesca Bruce

Brazil has also published its recent regulatory reliance regulations in English, a move designed to increase confidence in its decisions as it presses on with aligning its national practices with global best practices.

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

 
• By Sarah Karlin-Smith

The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

 
• By Sue Sutter

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.